WHO ICTRP trial
Utility of blood based DNA analysis for treatment modification in lung cancer.
CTRI/2022/05/042555 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2022/05/042555 |
|---|---|
| Public title | Utility of blood based DNA analysis for treatment modification in lung cancer. |
| Scientific title | Liquid biopsy-based risk stratification and intensification of treatment In EGFR mutant advanced NSCLC |
| Primary sponsor | All India Institute of Medical Sciences |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung |
| Interventions | Intervention1: geftinib with chemotherapy: Tablet Geftinib 250 mg, Route of administration- Orally with water, once daily with Pemetrexed 500mg/m2 + carboplatin AUC 5 Intervention2: Geftinib in combination with Chemotherapy: Geftinib in… |
| Registration date | May 13, 2022 |
| Target size | 31 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: